Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rhTSH-stimulated radioiodine ablation in differentiated thyroid cancer
NL-OMON23578Recruiting
- Sponsor
- Prof.dr. T.P. Links, endocrinologist
- Start
- Jun 2010
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Open-label, single-arm trial of thyrotropin alfa and iodine-131 in well-differentiated thyroid cancer (WDTC), sponsored by Prof.dr. T.P. Links, endocrinologist. Primary endpoints: Successful ablation and Ablation failure rate. Started Jun 2010; status: recruiting.
02
Drugs
thyrotropin alfaiodine-131
03
Conditions
well-differentiated thyroid cancer (WDTC)
Beyond the preview
Go deeper on NL-OMON23578.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON23578.